{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:30Z","timestamp":1790889930651,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,14]]},"DOI":"10.7759\/cureus.71476","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T22:38:37Z","timestamp":1728945517000},"source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Tetrabenazine in Reducing Chorea and Improving Motor Function in Individuals With Huntington's Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Nandini","family":"Vadlamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Ibrahimli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farees Ahmad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya Sai Satya","family":"Amaravadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poornachandra","family":"Nalisetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan P","year":"2018","unstructured":"McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol. 2018, 25:24-34. 10.1111\/ene.13413","journal-title":"Eur J Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez M","year":"2017","unstructured":"Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. 2017, 7:10.1101\/cshperspect.a024240","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2010.08.002","article-title":"Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease","volume":"33","author":"Milnerwood AJ","year":"2010","unstructured":"Milnerwood AJ, Raymond LA. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 2010, 33:513-23. 10.1016\/j.tins.2010.08.002","journal-title":"Trends Neurosci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2011.08.052","article-title":"Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function","volume":"198","author":"Raymond LA","year":"2011","unstructured":"Raymond LA, Andr\u00e9 VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience. 2011, 198:252-73. 10.1016\/j.neuroscience.2011.08.052","journal-title":"Neuroscience"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e328304b692","article-title":"Pathophysiology of Huntington\u2019s disease: from huntingtin functions to potential treatments","volume":"21","author":"Roze E","year":"2008","unstructured":"Roze E, Saudou F, Caboche J. Pathophysiology of Huntington\u2019s disease: from huntingtin functions to potential treatments. Curr Opin Neurol. 2008, 21:497-503. 10.1097\/WCO.0b013e328304b692","journal-title":"Curr Opin Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e3283550c97","article-title":"Huntington's disease","volume":"25","author":"Ha AD","year":"2012","unstructured":"Ha AD, Fung VS. Huntington's disease. Curr Opin Neurol. 2012, 25:491-8. 10.1097\/WCO.0b013e3283550c97","journal-title":"Curr Opin Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-170247","article-title":"What do we know about late onset Huntington's disease?","volume":"6","author":"Chaganti SS","year":"2017","unstructured":"Chaganti SS, McCusker EA, Loy CT. What do we know about late onset Huntington's disease?. J Huntingtons Dis. 2017, 6:95-103. 10.3233\/JHD-170247","journal-title":"J Huntingtons Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02494-7","article-title":"Juvenile Huntington's disease: two case reports and a review of the literature","volume":"14","author":"Lesinskien\u0117 S","year":"2020","unstructured":"Lesinskien\u0117 S, Rojaka D, Praninskien\u0117 R, Mork\u016bnien\u0117 A, Matulevi\u010dien\u0117 A, Utkus A. Juvenile Huntington's disease: two case reports and a review of the literature. J Med Case Rep. 2020, 14:10.1186\/s13256-020-02494-7","journal-title":"J Med Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1312","article-title":"A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion","volume":"50","author":"Margolis RL","year":"2001","unstructured":"Margolis RL, O'Hearn E, Rosenblatt A, et al.. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Ann Neurol. 2001, 50:373-80. 10.1002\/ana.1312","journal-title":"Ann Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis","volume":"27","author":"Pringsheim T","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012, 27:1083-91. 10.1002\/mds.25075","journal-title":"Mov Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29228","article-title":"Prevalence and incidence of Huntington's Disease: an updated systematic review and meta-analysis","volume":"37","author":"Medina A","year":"2022","unstructured":"Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and incidence of Huntington's Disease: an updated systematic review and meta-analysis. Mov Disord. 2022, 37:2327-35. 10.1002\/mds.29228","journal-title":"Mov Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2016-0008","article-title":"The global prevalence of Huntington's disease: a systematic review and discussion","volume":"6","author":"Baig SS","year":"2016","unstructured":"Baig SS, Strong M, Quarrell OW. The global prevalence of Huntington's disease: a systematic review and discussion. Neurodegener Dis Manag. 2016, 6:331-43. 10.2217\/nmt-2016-0008","journal-title":"Neurodegener Dis Manag"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2005.14.8.17929","article-title":"Caring for the carers: quality of life in Huntington's disease","volume":"14","author":"Aubeeluck A","year":"2005","unstructured":"Aubeeluck A. Caring for the carers: quality of life in Huntington's disease. Br J Nurs. 2005, 14:452-4. 10.12968\/bjon.2005.14.8.17929","journal-title":"Br J Nurs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-018-0312-x","article-title":"Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States","volume":"11","author":"Thorley EM","year":"2018","unstructured":"Thorley EM, Iyer RG, Wicks P, et al.. Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States. Patient. 2018, 11:547-59. 10.1007\/s40271-018-0312-x","journal-title":"Patient"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.21006","article-title":"Gene therapy for Huntington's disease: the final strategy for a cure?","volume":"15","author":"Byun S","year":"2022","unstructured":"Byun S, Lee M, Kim M. Gene therapy for Huntington's disease: the final strategy for a cure?. J Mov Disord. 2022, 15:15-20. 10.14802\/jmd.21006","journal-title":"J Mov Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.98.1.3","article-title":"Novel therapies in the search for a cure for Huntington's  disease","volume":"98","author":"Beal MF","year":"2001","unstructured":"Beal MF, Hantraye P. Novel therapies in the search for a cure for Huntington's  disease. Proc Natl Acad Sci U S A. 2001, 98:3-4. 10.1073\/pnas.98.1.3","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1021\/ml1000189","article-title":"Preparation and characterization of tetrabenazine enantiomers against vesicular monoamine transporter 2","volume":"1","author":"Yu QS","year":"2010","unstructured":"Yu QS, Luo W, Deschamps J, et al.. Preparation and characterization of tetrabenazine enantiomers against vesicular monoamine transporter 2. ACS Med Chem Lett. 2010, 1:105-9. 10.1021\/ml1000189","journal-title":"ACS Med Chem Lett"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/med.20187","article-title":"Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry","volume":"31","author":"Wimalasena K","year":"2011","unstructured":"Wimalasena K. Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev. 2011, 31:483-519. 10.1002\/med.20187","journal-title":"Med Res Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.20.1.125","article-title":"The role of vesicular transport proteins in synaptic transmission and neural degeneration","volume":"20","author":"Liu Y","year":"1997","unstructured":"Liu Y, Edwards RH. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci. 1997, 20:125-56. 10.1146\/annurev.neuro.20.1.125","journal-title":"Annu Rev Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00956-8","article-title":"The safety of deutetrabenazine for chorea in Huntington Disease: an open-label extension study","volume":"36","author":"Frank S","year":"2022","unstructured":"Frank S, Testa C, Edmondson MC, et al.. The safety of deutetrabenazine for chorea in Huntington Disease: an open-label extension study. CNS Drugs. 2022, 36:1207-16. 10.1007\/s40263-022-00956-8","journal-title":"CNS Drugs"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00127-8","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Furr Stimming E","year":"2023","unstructured":"Furr Stimming E, Claassen DO, Kayson E, et al.. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023, 22:494-504. 10.1016\/S1474-4422(23)00127-8","journal-title":"Lancet Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw331","article-title":"Meshable: searching PubMed abstracts by utilizing MeSH and MeSH-derived topical terms","volume":"32","author":"Kim S","year":"2016","unstructured":"Kim S, Yeganova L, Wilbur WJ. Meshable: searching PubMed abstracts by utilizing MeSH and MeSH-derived topical terms. Bioinformatics. 2016, 32:3044-6. 10.1093\/bioinformatics\/btw331","journal-title":"Bioinformatics"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA - a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA - a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch8","article-title":"Assessing risk of bias in a randomized trial","author":"Higgins JPT","year":"2019","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions, Second Edition. Wiley, 2019. 205-28. 10.1002\/9781119536604.ch8"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-018-0443-3","article-title":"Case study in major quotation errors: a critical commentary on the Newcastle-Ottawa scale","volume":"33","author":"Stang A","year":"2018","unstructured":"Stang A, Jonas S, Poole C. Case study in major quotation errors: a critical commentary on the Newcastle-Ottawa scale. Eur J Epidemiol. 2018, 33:1025-31. 10.1007\/s10654-018-0443-3","journal-title":"Eur J Epidemiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.12.009","article-title":"Systematic review of current guideline appraisals performed with the appraisal of guidelines for research & evaluation II instrument - a third of AGREE II users apply a cut-off for guideline quality","volume":"95","author":"Hoffmann-E\u00dfer W","year":"2018","unstructured":"Hoffmann-E\u00dfer W, Siering U, Neugebauer EA, Lampert U, Eikermann M. Systematic review of current guideline appraisals performed with the appraisal of guidelines for research & evaluation II instrument - a third of AGREE II users apply a cut-off for guideline quality. J Clin Epidemiol. 2018, 95:120-7. 10.1016\/j.jclinepi.2017.12.009","journal-title":"J Clin Epidemiol"},{"key":"ref28","unstructured":"Cochrane\u00a0consumers\u00a0and\u00a0communication\u00a0review\u00a0group.\u00a0data\u00a0synthesis\u00a0and\u00a0analysis. (2013). https:\/\/cccrg.cochrane.org\/sites\/cccrg.cochrane.org\/files\/public\/uploads\/AnalysisRestyled.pdf."},{"key":"ref29","article-title":"Guidance on the Conduct of Narrative Synthesis in Systematic Reviews: A Product From the ESRC Methods Programme","author":"Popay J","year":"2006","unstructured":"Popay J, Roberts H, Sowden A, et al.. Guidance on the Conduct of Narrative Synthesis in Systematic Reviews: A Product From the ESRC Methods Programme. 2006."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022, 18:10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref31","article-title":"Tetrabenazine in the treatment of Huntington's disease","volume":"3","author":"Paleacu D","year":"2007","unstructured":"Paleacu D. Tetrabenazine in the treatment of Huntington's disease. Neuropsychiatr Dis Treat. 2007, 3:545-51.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref32","article-title":"Tetrabenazine (Xenazine), an FDA-approved treatment option for Huntington\u2019s disease-related chorea","volume":"33","author":"Yero T","year":"2008","unstructured":"Yero T, Rey JA. Tetrabenazine (Xenazine), an FDA-approved treatment option for Huntington\u2019s disease-related chorea. P T. 2008, 33:690-4.","journal-title":"P T"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3180ca77ea","article-title":"A study of chorea after tetrabenazine withdrawal in patients with Huntington disease","volume":"31","author":"Frank S","year":"2008","unstructured":"Frank S, Ondo W, Fahn S, et al.. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008, 31:127-33. 10.1097\/WNF.0b013e3180ca77ea","journal-title":"Clin Neuropharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.79.s2a.06","article-title":"Comprehensive treatment of Huntington disease and other choreic disorders","volume":"79","author":"Singer C","year":"2012","unstructured":"Singer C. Comprehensive treatment of Huntington disease and other choreic disorders. Cleve Clin J Med. 2012, 79:30-4. 10.3949\/ccjm.79.s2a.06","journal-title":"Cleve Clin J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-013-0219-8","article-title":"Treatment of huntington disease","volume":"15","author":"Videnovic A","year":"2013","unstructured":"Videnovic A. Treatment of huntington disease. Curr Treat Options Neurol. 2013, 15:424-38. 10.1007\/s11940-013-0219-8","journal-title":"Curr Treat Options Neurol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S138828","article-title":"Review of deutetrabenazine: a novel treatment for chorea associated with Huntington\u2019s disease","volume":"12","author":"Dean M","year":"2018","unstructured":"Dean M, Sung VW. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington\u2019s disease. Drug Des Devel Ther. 2018, 12:313-19. 10.2147\/DDDT.S138828","journal-title":"Drug Des Devel Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S17152","article-title":"Management of Huntington's disease: role of tetrabenazine","volume":"7","author":"de Tommaso M","year":"2011","unstructured":"de Tommaso M, Serpino C, Sciruicchio V. Management of Huntington's disease: role of tetrabenazine. Ther Clin Risk Manag. 2011, 7:123-9. 10.2147\/TCRM.S17152","journal-title":"Ther Clin Risk Manag"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-9-62","article-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators","volume":"9","author":"Frank S","year":"2009","unstructured":"Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators. BMC Neurol. 2009, 9:10.1186\/1471-2377-9-62","journal-title":"BMC Neurol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease","volume":"4","author":"Claassen DO","year":"2017","unstructured":"Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D. Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. J Clin Mov Disord. 2017, 4:10.1186\/s40734-017-0051-5","journal-title":"J Clin Mov Disord"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology","volume":"79","author":"Armstrong MJ","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012, 79:597-603. 10.1212\/WNL.0b013e318263c443","journal-title":"Neurology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-012-0005-7","article-title":"Effect of tetrabenazine on motor function in patients with Huntington disease","volume":"1","author":"Ferrara JM","year":"2012","unstructured":"Ferrara JM, Mostile G, Hunter C, Adam OR, Jankovic J. Effect of tetrabenazine on motor function in patients with Huntington disease. Neurol Ther. 2012, 1:10.1007\/s40120-012-0005-7","journal-title":"Neurol Ther"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.7916\/D8BK1B2D","article-title":"Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with huntington's and other diseases","volume":"3","author":"Shen V","year":"2013","unstructured":"Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with huntington's and other diseases. Tremor Other Hyperkinet Mov (NY). 2013, 3:10.7916\/D8BK1B2D","journal-title":"Tremor Other Hyperkinet Mov (NY)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.09.053","article-title":"Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease","volume":"347","author":"Kegelmeyer DA","year":"2014","unstructured":"Kegelmeyer DA, Kloos AD, Fritz NE, Fiumedora MM, White SE, Kostyk SK. Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease. J Neurol Sci. 2014, 347:219-23. 10.1016\/j.jns.2014.09.053","journal-title":"J Neurol Sci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S6430","article-title":"Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease","volume":"6","author":"Frank S","year":"2010","unstructured":"Frank S. Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat. 2010, 6:657-65. 10.2147\/NDT.S6430","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1876666","article-title":"State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease","volume":"22","author":"Gibson JS","year":"2021","unstructured":"Gibson JS, Claassen DO. State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease. Expert Opin Pharmacother. 2021, 22:1015-24. 10.1080\/14656566.2021.1876666","journal-title":"Expert Opin Pharmacother"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006, 66:366-72. 10.1212\/01.wnl.0000198586.85250.13","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/193482-efficacy-and-safety-of-tetrabenazine-in-reducing-chorea-and-improving-motor-function-in-individuals-with-huntingtons-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T22:38:42Z","timestamp":1728945522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/193482-efficacy-and-safety-of-tetrabenazine-in-reducing-chorea-and-improving-motor-function-in-individuals-with-huntingtons-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.71476","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}